Clinical Benefit and Toxicity of mirvetuximab soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer：A systematic review and Single-Arm meta-analysis
Fields of Study & Subjects
Ovarian cancer diagnosis and treatment
PARP inhibition in cancer therapy
Ovarian function and disorders
Publication details
- Publication date
- 15 March 2026
- Language
- EN